Madrigal Pharmaceuticals, Inc. MDGL
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a GI/hepatology drug developer. Its lead program, Rezdiffra (resmetirom), is in Phase 3 for MASH (metabolic dysfunction-associated steatohepatitis). Its next catalyst on record is Rezdiffra - MAESTRO-CSPH trial: Trial initiation (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Rezdiffra - MAESTRO-CSPH trial — Trial initiation (H1 2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Rezdiffra (resmetirom) | noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3) | small molecule | Approved |
| Rezdiffra (resmetirom) | compensated MASH cirrhosis (F4c) | small molecule | Phase 3 |
| MGL-2086 | MASH | small molecule | Pre-clinical |
| ervogastat | MASH | small molecule | Pre-clinical |
| MGL-0795 (formerly ARO-PNPLA3) | MASH (PNPLA3 mutation) | RNA (siRNA/ASO/mRNA) | Pre-clinical |
Recent results and decisions
- Nov 3, 2026started Madrigal plans to initiate MAESTRO-CSPH, a Phase 3 event-driven outcomes trial in well-compensated MASH cirrhosis patients enriched for clinically significant portal hypertension.
Madrigal plans to initiate MAESTRO-CSPH, a second Phase 3 event-driven outcomes trial that builds on its ongoing MAESTRO-NASH OUTCOMES study.
Filing - Nov 3, 2026n/a Madrigal plans to initiate MAESTRO-CSPH, a second Phase 3 event-driven outcomes trial for resmetirom in F4c patients enriched for CSPH in the first half of 2027.
Trial initiation is expected in the first half of 2027, subject to regulatory discussions.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.